Publications by authors named "Xupeiyao Shi"
Tumor-specific T cells play a crucial role in tumor immunity. However, these cells are often scarce and functionally exhausted within the tumor microenvironment (TME), leading to the limited efficacy of immunotherapy in many cancer patients. In contrast, increasing evidence suggests that the TME is rich in "bystander" T cells (T), most of which are virus-specific and unrelated to the tumor.
View Article and Find Full Text PDFNitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy.
Cancer Immunol Immunother
October 2024
Neoantigen vaccines represent an emerging and promising strategy in the field of tumor immunotherapy. Despite their potential, designing an effective neoantigen vaccine remains a challenge due to the current limitations in predicting CD4 T cell epitopes with high accuracy. Here, we introduce a novel approach to neoantigen vaccine design that does not rely on computational prediction of CD4 T cell epitopes.
View Article and Find Full Text PDFArticle Synopsis
- Personalized neoantigen therapy can help some cancer patients, but not everyone has enough of the right markers (neoantigens) for it to work.
- Some mutations in tumors don't make the immune system react, meaning some patients won't benefit from this treatment.
- Scientists suggest using a special ingredient called p-nitrophenylalanine (pNOPhe) to tweak these mutations, making them better at activating the immune system and possibly helping more patients be treated successfully.